GlassScriptPhysician profile
Mebin B Thomas
NPI 1598082737
$323,040.63
in general payments reported to CMS, 2019-2025
21 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $36K · 2023: $130K · 2024: $82K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $213K · Travel and Lodging: $33K · Food and Beverage: $12K · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,912.50 |
| Travel and Lodging | $33,266.38 |
| Food and Beverage | $12,456.52 |
| Education | $351.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $176,164.51 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $133,679.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $8,622.97 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $881.75 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $704.51 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $597.87 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $539.18 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.75 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $258.38 | 2024-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $180.36 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $174.28 | 2023-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $157.88 | 2025 | Cobenfy |
| Bausch Health US, LLC | $135.51 | 2024-2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $106.20 | 2022-2025 | Fanapt |
| Lundbeck LLC | $95.67 | 2022-2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $88.55 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $75.92 | 2022 | |
| Noven Therapeutics, LLC | $57.21 | 2023-2024 | Xelstrym, Secuado |
| Sage Therapeutics, LLC | $47.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.50 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mebin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.